Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
$ 314.99KDepreciation, Amortization & Accretion
VS
Market
Sector
Industry
History
$ 14.15Close
$ 6.7 - $ 682.84 52-Week Range
Ticker Information
Ticker
RNAZCompany Name
TRANSCODE THERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQTRANSCODE THERAPEUTICS INC - Depreciation, Amortization & Accretion Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
RNAZ - DepAmor Historical data
| Date | Depreciation, Amortization & Accretion |
|---|---|
| 6/30/2025 | $ 314.99K |
| 3/31/2025 | $ 444.38K |
| 12/31/2024 | $ 534.86K |
| 9/30/2024 | $ 552.17K |
| 6/30/2024 | $ 563.44K |
| 3/31/2024 | $ 558.19K |
| 12/31/2023 | $ 516.75K |
| 9/30/2023 | $ 406.08K |
| 6/30/2023 | $ 292.1K |
| 3/31/2023 | $ 177.2K |
Key Performance Insights, Last 5 Years
- TRANSCODE THERAPEUTICS INC's latest trailing twelve months (TTM) DepAmor stands at $ 0.
- Over the past 5 years, TRANSCODE THERAPEUTICS INC's average DepAmor has been $ 296.44K.
- The median DepAmor for TRANSCODE THERAPEUTICS INC during this period was $ 303.54K
- TRANSCODE THERAPEUTICS INC reached its highest DepAmor over the past 5 years at $ 563.44K.
- The lowest DepAmor recorded by TRANSCODE THERAPEUTICS INC in the same timeframe $ 0
Similar metrics to DepAmor:
- Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) - [Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
- Depreciation and Amortization Margin - [Calculation] The company’s deprecation and amortization [DepAmor] expressed as a percentage of [Revenue].
- Net Cash Flow - Operations - [Cash Flow Statement] Cash flow from operations represents the amount of cash inflow (outflow) that a company generates (consumes) from operating activities. Similar to Net Income [NetIncCmn] but harder to manipulate and ignoring effects of non-cash charges like depreciation.
- Stock Based Compensation - [Cash Flow Statement] Stock Based Compensation, also called Share Based Compensation or Equity Compensation, is a method of paying directors, executives and employees with equity in the business. As non-cash expense, this element is added back when calculating net cash generated by operating activities [NCFO].
- Earnings per Share - [Income Statement] Earnings per Share as calculated and reported by the company. Approximates to the amount of net income [NetIncCmn] divided by the weighted average number of shares [SharesWA] after adjusting for [ShareFactor].
Definition of Depreciation, Amortization & Accretion
[Cash Flow Statement] A component of operating cash flow [NCFO] representing the aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a non-cash item, the net amount is added back to net income when calculating cash provided by operations.RNAZ - Depreciation, Amortization & Accretion, Last 5 years
$ 0
Minimum
Dec 31, 2020
$ 563.44K
Maximum
Jun 30, 2024
$ 296.44K
Average
$ 303.54K
Median
DepAmor Benchmark AnalysisMarket
The chart above depicts the distribution of DepAmor for companies in the Total Stock Market. The average DepAmor of the companies is $ 24.27M with a standard deviation of $ 33.87M.
The following table provides additional summary stats:
DepAmor in the Market:
| filtered constituents | 3.16K |
|---|---|
| min | $ -81M |
| max | $ 136.98M |
| average | $ 24.27M |
| median | $ 6.85M |
| std | $ 33.87M |